| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3)：209-249.
|
| [2] |
Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with Fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy[J]. J Clin Oncol, 2017, 35(25)：2875-2884.
|
| [3] |
Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer--An overview and update[J]. Mol Cell Endocrinol, 2015, 418 Pt 3(3)：220-234.
|
| [4] |
Milani A, Geuna E, Mittica G, et al. Overcoming endocrine resistance in metastatic breast cancer: current evidence and future directions[J]. World J Clin Oncol, 2014, 5(5)：990-1001.
|
| [5] |
Roberto M, Astone A, Botticelli A, et al. CDK4/6 inhibitor treatments in patients with hormone receptor positive, HER2 negative advanced breast cancer: potential molecular mechanisms, clinical implications and future perspectives[J]. Cancers (Basel), 2021，13(2)：332.
|
| [6] |
Harashima H, Dissmeyer N, Schnittger A. Cell cycle control across the eukaryotic kingdom[J]. Trends Cell Biol, 2013, 23(7)：345-356.
|
| [7] |
Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy[J]．Cancer Discov, 2016, 6(4)：353-367.
|
| [8] |
Hirai H, Kawanishi N, Iwasawa Y. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases[J]. Curr Top Med Chem, 2005, 5(2)：167-179.
|
| [9] |
Asghar U，Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy[J]. Nat Rev Drug Discov, 2015，14(2)：130-146.
|
| [10] |
U. S. Food and Drug Adnimistation. Novel drug approvals for 2015[EB/OL]. [2019-11-15].
URL
|
| [11] |
U. S. Food and Drug Adnimistation. Novel drug approvals for 2017[EB/OL]. [2019-11-15].
URL
|
| [12] |
Robert M, Frenel JS, Bourbouloux E, et al. An update on the clinical use of CDK4/6 inhibitors in breast cancer[J]. Drugs, 2018, 78(13)：1353-1362.
|
| [13] |
Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2021, 22(2)：212-222.
|
| [14] |
Sammons S, Shastry M, Dent S, et al. Practical treatment strategies and future directions after progression while receiving CDK4/6 inhibition and endocrine therapy in advanced HR+/HER2- breast cancer[J]. Clin Breast Cancer, 2020, 20(1)：1-11.
|
| [15] |
Kim ES. Abemaciclib: first global approval[J]. Drugs, 2017, 77(18)：2063-2070.
|
| [16] |
Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro[J]. Breast Cancer Res, 2009，11(5)：R77.
|
| [17] |
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med, 2016, 375(20)：1925-1936.
|
| [18] |
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for hr-positive, advanced breast cancer[J]. N Engl J Med, 2016, 375(18)：1738-1748.
|
| [19] |
Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer [J]. J Clin Oncol, 2017；35(32)：3638-3646.
|
| [20] |
Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3[J]. J Clin Oncol, 2018, 36(24)：2465-2472.
|
| [21] |
Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): arandomised phase 3 trial[J]. Lancet Oncol, 2018，19(7)：904-915.
|
| [22] |
Zhang QY, Sun T, Yin YM, et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study[J]. Ther Adv Med Oncol, 2020，12：1758835920963925.
|
| [23] |
Xu B, Zhang Q, Zhang P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial[J]. Nat Med, 2021；27(11)：1904-1909.
|
| [24] |
Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update[J]. J Clin Oncol, 2021，39(35)：3959-3977.
|
| [25] |
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC5)[J]. Ann Oncol, 2020, 31(12): 1623-1649.
|
| [26] |
Gradishar WJ, Moran MS, Abraham J, et al. NCCN guidelines® insights: breast cancer, version 4.2021[J]. J Natl Compr Canc Netw, 2021, 19(5): 484-493.
|
| [27] |
李健斌，江泽飞. 2021年中国临床肿瘤学会乳腺癌诊疗指南更新要点解读[J]. 中华医学杂志，2021, 101(24): 1835-1838.
|
| [28] |
Condorelli R, Spring L, O’Shaughnessy J, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer[J]. Ann Oncol, 2018，29(3)：640-645.
|
| [29] |
Li Z, Razavi P, Li Q, et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway[J]. Cancer Cell, 2018, 34(6): 893-905.
|
| [30] |
Etemadmoghadam D, Au-Yeung G, Wall M, et al. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer[J]. Clin Cancer Re, 2013，19(21)：5960-5971.
|
| [31] |
Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors[J]. Cancer Discov, 2016, 6(7): 740-753.
|
| [32] |
Jansen VM, Bhola NE, Bauer JA, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer[J]. Cancer Res, 2017, 77(9): 2488-2499.
|
| [33] |
Formisano L, Lu Y, Servetto A, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer[J]. Nat Commun, 2019, 10(1): 1373.
|
| [34] |
Yang C, Li Z, Bhatt T, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence [J]. Oncogene, 2017，36(16)：2255-2264.
|
| [35] |
Li Y, Li W, Gong C, et al. A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer[J]. Ther Adv Med Oncol, 2021，13：17588359211022890.
|
| [36] |
Wander S, Han H, Zangardi ML, et al. Clinical outcomes with abemaciclib after prior CDK4/6 inhibitor progression in breast cancer: a multicenter experience[EB/OL]. [2021-03-24]．
URL
|
| [37] |
Bardia A, Huvitz SA, Demichele A, et al. Phase Ⅰ/Ⅱ trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1)[J]. Clin Cancer Res, 2021，27(15)：4177-4185.
|
| [38] |
Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study[J]. Lancet Oncol, 2021，22(4)：489-498.
|
| [39] |
Cook MM, Rabadi LA, Kaempf AJ, et al. Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4/6 inhibitor therapy[J]. Oncologist, 2021, 26(2)：101-106.
|
| [40] |
Johnston SRD, Harbeck N, Hegg R, et al. abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+，HER2-，node-positive, high-risk, early breast cancer (MonarchE)[J]. J Clin Oncol, 2020, 38(34)：3987-3998.
|
| [41] |
Loibl S, Marme F, Martin M, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the penelopeb trial[J]. J Clin Oncol, 2021，39(14)：1518-1530.
|
| [42] |
Johnston S, Puhalla S, Wheatley D, et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial[J]. J Clin Oncol, 2019, 37(3)：178-189.
|
| [43] |
Khan QJ, O’dea A, Bardia A, et al. Letrozole+ ribociclib versus letrozole+ placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial)[J]. J Clin Oncol, 2020, 38(15_suppl)：505.
|
| [44] |
Prat A, Saura C, Pascual T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial[J]. Lancet Oncol, 2020，21(1)：33-43.
|
| [45] |
Cottu P, D’hondt V, Dureau S, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer[J]. Ann Oncol, 2018，29(12)：2334-2340.
|
| [46] |
Delaloge S, Dureau S, D’hondt V, et al. Abstract PS12-03: Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study [EB/OL]. [2020-12-08].
URL
|
| [47] |
Matutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease [J]. Ther Adv Med Oncol, 2018，10：1758835918818346.
|
| [48] |
Agostinetto E, Debien V, Marta GN, et al. CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer[J]. Eur J Clin Invest, 2021，51(7)：e13535.
|
| [49] |
Ciruelos E, Villagrasa P, Pascual T, et al. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial[J]. Clin Cancer Res, 2020, 26(22)：5820-5829.
|
| [50] |
Tolaney SM, Wardley AM, Zambelli S, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2020，21(6)：763-775.
|
| [51] |
Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13(11): 674-690.
|
| [52] |
Liu YR, Jiang YZ, Xu XE, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer[J]. Breast Cancer Res, 2016, 18(1): 33.
|
| [53] |
Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4/6 inhibition in triplenegative breast cancer[J]. Clin Cancer Res, 2017, 23(18): 5561-5572.
|
| [54] |
Liu CY, Lau KY, Hsu CC, et al. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells[J]. PLoS One, 2017, 12(12): e189007.
|
| [55] |
Teo ZL, Versaci S, Dushyanthen S, et al. Combined CDK4/6 and PI3Kα inhibition is synergistic and immunogenic in triple-negative breast cancer[J]. Cancer Res, 2017, 77(22): 6340-6352.
|
| [56] |
Goel S, Decristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity[J]. Nature, 2017, 548(7668): 471-475.
|
| [57] |
Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance[J]. Nature, 2018, 553(7686): 91-95.
|
| [58] |
Yuan Y, Lee JS, Yost SE, et al. Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer[J]. Eur J Cancer, 2021，154：11-20.
|
| [59] |
Borstkanker Onderzoek Group. Endocrine therapy plus CDK4/6 in first or second line for hormone (SONIA) receptor positive advanced breast cancer [EB/OL]. [2021-02-08].
URL
|
| [60] |
International Cancer Research Group. Fulvestrant versus fulvestrant plus palbociclib in operable breast cancer responding to fulvestrant (SAFIA) [EB/OL]. [2021-02-27].
URL
|
| [61] |
International Breast Cancer Study Group. Palbociclib for HR positive / HER2-negative isolated locoregional recurrence of breast cancer (POLAR) [EB/OL]. [2021-01-29].
URL
|
| [62] |
Institute of Cancer Research. Preoperative endocrine therapy for individualised care with abemaciclib (POETIC-A) [EB/OL]. [2020-10-14].
URL
|
| [63] |
Novartis Pharmaceuticals. A trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer (NATALEE) [EB/OL]．[2021-10-10].
URL
|
| [64] |
Janni W. Chevendo (Chemo vs. Endo)[EB/OL]. [2021-01-26].
URL
|